XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for the financial year ended December 31, 2023, and the interim period ended June 30, 2024, following a review by the Alberta Securities Commission. The amended YE 2023 MD&A now includes a full definition of Disclosure Controls and Procedures as per NI 52-109, addressing the previously abbreviated version.The Q2 2024 MD&A update provides additional information on the use of funds for the company's product candidates and estimated costs in the Outlook section. These amendments, approved by the company's Board of Directors on September 12, 2024, do not reflect any events occurring after the original filing dates or update other information from the original documents.XORTX, a late-stage clinical pharmaceutical company, is developing innovative therapies for progressive kidney disease. Their lead program, XRx-008, targets ADPKD, while XRx-101 focuses on acute kidney injury associated with COVID-19. The company is also advancing a pre-clinical program, XRx-225, for Type 2 Diabetic Nephropathy.

XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for the financial year ended December 31, 2023, and the interim period ended June 30, 2024, following a review by the Alberta Securities Commission. The amended YE 2023 MD&A now includes a full definition of Disclosure Controls and Procedures as per NI 52-109, addressing the previously abbreviated version.The Q2 2024 MD&A update provides additional information on the use of funds for the company's product candidates and estimated costs in the Outlook section. These amendments, approved by the company's Board of Directors on September 12, 2024, do not reflect any events occurring after the original filing dates or update other information from the original documents.XORTX, a late-stage clinical pharmaceutical company, is developing innovative therapies for progressive kidney disease. Their lead program, XRx-008, targets ADPKD, while XRx-101 focuses on acute kidney injury associated with COVID-19. The company is also advancing a pre-clinical program, XRx-225, for Type 2 Diabetic Nephropathy.